Aetna modified CPB 0883 for ramucirumab (Cyramza), effective December 20, 2025. Here's what billing teams need to know before submitting claims under this updated coverage policy.
Aetna, a CVS Health company, updated Clinical Policy Bulletin 0883 governing ramucirumab (Cyramza) coverage for commercial medical plans. The revised policy expands approved indications to include thymic carcinoma and mesothelioma, tightens the line-item criteria for NSCLC continuation therapy, and adds specificity around colorectal cancer variants. The primary billing code is HCPCS J9308 (injection, ramucirumab, 5 mg), administered under CPT 96413 and 96415. Every claim under this policy requires precertification before treatment begins.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Ramucirumab (Cyramza) — CPB 0883 |
| Policy Code | CPB 0883 |
| Change Type | Modified |
| Effective Date | December 20, 2025 |
| Impact Level | High |
| Specialties Affected | Medical Oncology, Hematology/Oncology, Gastroenterology, Thoracic Oncology, Hepatology |
| Key Action | Confirm precertification and indication-specific criteria before billing J9308 for any new or continuing patient |
Aetna Ramucirumab Coverage Criteria and Medical Necessity Requirements 2025
The Aetna ramucirumab coverage policy under CPB 0883 is indication-driven. Aetna will not cover J9308 without precertification. Call (866) 752-7021 or fax (888) 267-3277 before initiating therapy.
Medical necessity approval depends entirely on which cancer type you're treating, what line of therapy this is, and which combination regimen is being used. Get those details locked in before you submit. If any of those elements are off, you're looking at a claim denial.
Here's how each indication breaks down:
Gastric, GEJ, EGJ, and Esophageal Adenocarcinoma
Ramucirumab is covered as subsequent therapy only — not first-line. Aetna accepts it as a single agent, in combination with paclitaxel (J9267), or in combination with irinotecan (J9206) with or without fluorouracil (J9190). The member must be a non-surgical candidate or have unresectable, locally advanced, recurrent, or metastatic disease.
Non-Small Cell Lung Cancer (NSCLC)
Two pathways exist here. First: in combination with docetaxel as subsequent therapy. Second: in combination with erlotinib for members with EGFR exon 19 deletion or exon 21 (L858R) substitution mutation. That second pathway requires molecular confirmation — order CPT 81235 before you request prior authorization for the erlotinib combination.
Colorectal Cancer (CRC)
This is one of the broader approvals. Aetna covers ramucirumab for advanced or metastatic CRC — and this explicitly includes anal adenocarcinoma (ICD-10 C21.x) and appendiceal adenocarcinoma. The required regimen is FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) or irinotecan alone.
Hepatocellular Carcinoma (HCC)
This is one of the most restrictive indications. Aetna only covers ramucirumab as subsequent therapy for progressive HCC when the member has an alpha-fetoprotein (AFP) of 400 ng/mL or greater. Run CPT 82105 or 82107 before submitting the prior auth. If the AFP doesn't hit that threshold, the claim will not clear medical necessity review.
Mesothelioma
This is new territory in the updated policy. Aetna now covers subsequent treatment of pleural mesothelioma, pericardial mesothelioma, or tunica vaginalis testis mesothelioma — but only when ramucirumab is used in combination with gemcitabine (J9198 or J9201). Single-agent ramucirumab for mesothelioma is not covered.
Thymic Carcinoma
Also newly addressed in this update. Three scenarios qualify: recurrent/advanced/metastatic disease treated with carboplatin (J9045) plus paclitaxel, then continued as single-agent maintenance; R1 or R2 resection with postoperative carboplatin/paclitaxel; or surgically resectable disease where R0 is uncertain, used preoperatively with carboplatin/paclitaxel. Make sure the clinical documentation specifies the resection classification or disease stage before submitting.
Aetna Ramucirumab Exclusions and Non-Covered Indications
Aetna's position is direct: all indications not listed in Section I of CPB 0883 are experimental, investigational, or unproven.
Two specific exclusions are spelled out in the code-level guidance. Cisplatin (J9060) is not covered in combination with ramucirumab. Dacarbazine (J9130) is not covered in combination with ramucirumab for pancreatic neuroendocrine tumors. If your oncologist is using either of those combinations, don't submit — the denial is built into the policy.
Small-cell lung cancer is also excluded from coverage under the lung cancer codes (C34.x). The ICD-10 annotations call this out explicitly. Billing ramucirumab with a small-cell diagnosis will not meet medical necessity under this coverage policy.
Coverage Indications at a Glance
| Indication | Status | Key HCPCS/CPT | Notes |
|---|---|---|---|
| Gastric/GEJ/EGJ/Esophageal Adenocarcinoma (unresectable, recurrent, or metastatic) | Covered | J9308, J9267, J9206, J9190 | Subsequent therapy only; single agent or combo |
| NSCLC — docetaxel combination | Covered | J9308 | Subsequent therapy; EGFR testing not required |
| NSCLC — erlotinib combination | Covered | J9308, CPT 81235 | EGFR exon 19 del or exon 21 L858R required |
| Colorectal Cancer (incl. anal & appendiceal adenocarcinoma) | Covered | J9308, J9206, J9190 | FOLFIRI or irinotecan regimen required |
| Hepatocellular Carcinoma | Covered | J9308, CPT 82105/82107 | AFP ≥ 400 ng/mL required; subsequent therapy only |
| Pleural/Pericardial/Tunica Vaginalis Testis Mesothelioma | Covered | J9308, J9198/J9201 | Must be used with gemcitabine; subsequent therapy |
| Thymic Carcinoma — recurrent/advanced/metastatic | Covered | J9308, J9045, J9267 | Carboplatin + paclitaxel, then single-agent maintenance |
| Thymic Carcinoma — R1/R2 resection (postoperative) | Covered | J9308, J9045, J9267 | Postoperative treatment with carboplatin + paclitaxel |
| Thymic Carcinoma — preoperative (R0 uncertain) | Covered | J9308, J9045, J9267 | Requires documentation that R0 is uncertain |
| Small-cell lung cancer | Not Covered | — | Explicitly excluded under C34.x codes |
| Ramucirumab + cisplatin | Not Covered | J9060 | Combination with cisplatin excluded |
| Ramucirumab + dacarbazine for pancreatic neuroendocrine tumor | Not Covered | J9130 | Combination excluded for this indication |
| All other indications | Experimental / Not Covered | — | Considered investigational under CPB 0883 |
Aetna Ramucirumab Billing Guidelines and Action Items 2025
The effective date of December 20, 2025 is already here. If you're still working from the prior version of CPB 0883, your precertification submissions may be using outdated criteria.
| # | Action Item |
|---|---|
| 1 | Update your precertification workflow for J9308 now. Confirm your team is using the updated CPB 0883 criteria for all new prior authorization requests. The precertification line is (866) 752-7021. Do not submit without it — ramucirumab billing without precertification will result in claim denial across all plan designs. |
| 2 | Add AFP documentation to your HCC precertification checklist. For hepatocellular carcinoma patients, CPT 82105 (AFP serum) or 82107 (AFP-L3 fraction) must be on file and showing AFP ≥ 400 ng/mL before you submit. Missing this is the single most common reason HCC ramucirumab claims fail medical necessity review. |
| 3 | Require EGFR mutation documentation for the erlotinib NSCLC pathway. If your oncologist is using ramucirumab plus erlotinib, CPT 81235 must be completed and documented before prior auth submission. EGFR exon 19 deletion or exon 21 (L858R) is the required finding. Any other mutation does not qualify. |
| 4 | Document resection classification for thymic carcinoma claims. R1 or R2 resection status — or a documented assessment that R0 is uncertain — is required for thymic carcinoma coverage. If the operative or pathology report doesn't specify this, the claim will not meet medical necessity. Work with your clinical team to ensure this language is in the chart before December 20, 2025 cases go out the door. |
| 5 | Flag cisplatin and dacarbazine combination orders. If your charge capture or order entry system allows J9060 (cisplatin) or J9130 (dacarbazine) to be ordered alongside J9308, add a billing edit or charge router alert. These combinations are explicitly excluded. An automatic hard stop is cleaner than a denial and appeal. |
| 6 | Review reauthorization criteria for active NSCLC patients. Continuation of ramucirumab for NSCLC now has two distinct pathways. The standard path requires no evidence of unacceptable toxicity or disease progression. There is also a T790M-negative pathway that allows continuation without progression evidence. Confirm which pathway applies to each reauthorization — submitting under the wrong criteria will trigger a denial. |
| 7 | Confirm plan design applicability. CPB 0883 applies to commercial plans only. For Medicare patients, Aetna uses separate criteria through the Medicare Part B step program. Do not apply CPB 0883 criteria to Medicare claims. If you're unsure which plan design governs a specific member, pull the eligibility and benefits check before submitting. |
If your oncology billing mix includes a high volume of HCC, mesothelioma, or thymic carcinoma cases, talk to your compliance officer before December 20, 2025. The mesothelioma and thymic carcinoma indications are new to this policy, and your prior auth submission templates may not yet reflect the required combination regimen documentation.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Ramucirumab Under CPB 0883
Covered HCPCS Code (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J9308 | HCPCS | Injection, ramucirumab, 5 mg |
CPT Codes Related to CPB 0883
| Code | Type | Description |
|---|---|---|
| 81235 | CPT | EGFR gene analysis, common variants (e.g., non-small cell lung cancer) |
| 82105 | CPT | Alpha-fetoprotein (AFP); serum |
| 82107 | CPT | Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio) |
| 96413 | CPT | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
| 96415 | CPT | Chemotherapy administration, IV infusion; each additional hour |
Combination Agent HCPCS Codes Referenced in CPB 0883
| Code | Type | Description | Notes |
|---|---|---|---|
| J0640 | HCPCS | Injection, leucovorin calcium, per 50 mg | Used in FOLFIRI regimen |
| J8520 | HCPCS | Capecitabine, oral, 150 mg | Referenced combination agent |
| J8521 | HCPCS | Capecitabine, oral, 500 mg | Referenced combination agent |
| J9022 | HCPCS | Injection, atezolizumab, 10 mg | Referenced combination agent |
| J9024 | HCPCS | Injection, atezolizumab, 5 mg and hyaluronidase-tqjs | Referenced combination agent |
| J9035 | HCPCS | Injection, bevacizumab, 10 mg | Referenced combination agent |
| J9045 | HCPCS | Injection, carboplatin, 50 mg | Thymic carcinoma regimen |
| J9060 | HCPCS | Injection, cisplatin, powder or solution, 10 mg | Not covered in combination with ramucirumab |
| J9130 | HCPCS | Dacarbazine, 100 mg | Not covered in combination with ramucirumab for pancreatic neuroendocrine tumor |
| J9190 | HCPCS | Injection, fluorouracil, 500 mg | Covered in combination for metastatic small intestine adenocarcinoma |
| J9198 | HCPCS | Injection, gemcitabine hydrochloride (infugem), 100 mg | Mesothelioma regimen |
| J9201 | HCPCS | Injection, gemcitabine hydrochloride, NOS, 200 mg | Mesothelioma regimen |
| J9206 | HCPCS | Injection, irinotecan, 20 mg | Covered in combination for metastatic small intestine adenocarcinoma; CRC |
| J9263 | HCPCS | Injection, oxaliplatin, 0.5 mg | Referenced combination agent |
| J9264 | HCPCS | Injection, paclitaxel protein-bound particles, 1 mg | Referenced combination agent |
| J9267 | HCPCS | Injection, paclitaxel, 1 mg | Gastric/GEJ and thymic carcinoma regimens |
| J9400 | HCPCS | Injection, ziv-aflibercept, 1 mg | Referenced combination agent |
| Q5107 | HCPCS | Injection, bevacizumab-awwb, biosimilar (mvasi), 10 mg | Referenced combination agent |
Key ICD-10-CM Diagnosis Codes Covered Under CPB 0883
| Code Range / Code | Description |
|---|---|
| C15.3–C20 | Malignant neoplasm of esophagus, stomach, small intestine (including duodenum), colon, rectosigmoid junction, and rectum |
| C21.0–C21.8 | Malignant neoplasm of anus — covered in combination with FOLFIRI for metastatic anal adenocarcinoma |
| C22.0–C22.9 | Liver cell carcinoma and malignant neoplasm of liver and intrahepatic bile ducts (HCC) |
| C24.0–C24.9 | Malignant neoplasm of other and unspecified parts of biliary tract |
| C34.0–C34.29 (and further subsets) | Malignant neoplasm of bronchus and lung — NSCLC only; small-cell lung cancer explicitly excluded |
The full ICD-10 code set for CPB 0883 includes 193 codes. The ranges above represent the primary covered diagnosis categories. Confirm full code applicability in the complete CPB 0883 document before billing.
Get the Full Picture for CPT 96413
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.